Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

Also called NCT05888103

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05888103
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05888103. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-11 (actual); primary completion 2024-04-02 (actual). Results posted on 2025-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Acronym
V-Mono China
Condition
Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention (Drug)
Inclisiran
Intervention (Drug)
Matching Placebo for Inclisiran
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05888103
Content hash
e9ad5b45a7019580f1d7d5ffcb19fdf0fd9546af1efd5a556c19b325cb4eef06